{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:55:11Z","timestamp":1753890911497,"version":"3.41.2"},"reference-count":68,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T00:00:00Z","timestamp":1712275200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009887","name":"Regione Siciliana","doi-asserted-by":"publisher","award":["CUP G89J18000700007"],"award-info":[{"award-number":["CUP G89J18000700007"]}],"id":[{"id":"10.13039\/501100009887","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Genet."],"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>In the precision medicine era, identifying predictive factors to select patients most likely to benefit from treatment with immunological agents is a crucial and open challenge in oncology.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>This paper presents a pan-cancer analysis of Tumor Mutational Burden (TMB). We developed a novel computational pipeline, TMBcalc, to calculate the TMB. Our methodology can identify small and reliable gene signatures to estimate TMB from custom targeted-sequencing panels. For this purpose, our pipeline has been trained on top of 17 cancer types data obtained from TCGA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Our results show that TMB, computed through the identified signature, strongly correlates with TMB obtained from whole-exome sequencing (WES).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>We have rigorously analyzed the effectiveness of our methodology on top of several independent datasets. In particular we conducted a comprehensive testing on: (i) 126 samples sourced from the TCGA database; few independent whole-exome sequencing (WES) datasets linked to colon, breast, and liver cancers, all acquired from the EGA and the ICGC Data Portal. This rigorous evaluation clearly highlights the robustness and practicality of our approach, positioning it as a promising avenue for driving substantial progress within the realm of clinical practice.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fgene.2024.1285305","type":"journal-article","created":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T04:19:27Z","timestamp":1712290767000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["TMBcalc: a computational pipeline for identifying pan-cancer Tumor Mutational Burden gene signatures"],"prefix":"10.3389","volume":"15","author":[{"given":"Grete Francesca","family":"Privitera","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Alaimo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Caruso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo","family":"Ferro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Forte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo","family":"Pulvirenti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,4,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"54572","DOI":"10.18632\/oncotarget.9788","article-title":"Post-transcriptional knowledge in pathway analysis increases the accuracy of phenotypes classification","volume":"7","author":"Alaimo","year":"2016","journal-title":"Oncotarget"},{"key":"B2","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3390\/ncrna3020020","article-title":"Detecting disease specific pathway substructures through an integrated systems biology approach","volume":"3","author":"Alaimo","year":"2017","journal-title":"Noncoding RNA"},{"key":"B3","doi-asserted-by":"publisher","first-page":"703","DOI":"10.21037\/tlcr.2018.08.14","article-title":"Implementing tumor mutational burden (TMB) analysis in routine diagnostics-a primer for molecular pathologists and clinicians","volume":"7","author":"Allg\u00e4uer","year":"2018","journal-title":"Transl. Lung Cancer Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1002\/ijc.31878","article-title":"Size matters: dissecting key parameters for panel-based tumor mutational burden analysis","volume":"144","author":"Buchhalter","year":"2018","journal-title":"Int. J. Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"34221","DOI":"10.18632\/oncotarget.5950","article-title":"Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice","volume":"6","author":"Campesato","year":"2015","journal-title":"Oncotarget"},{"volume-title":"Classification and regression training","year":"2016","key":"B6"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","article-title":"Pd-1 blockade in mismatch repair-deficient, locally advanced rectal cancer","volume":"386","author":"Cercek","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2361507","DOI":"10.1155\/2022\/2361507","article-title":"Characterization of the immune microenvironmental landscape of lung squamous cell carcinoma with immune cell infiltration","volume":"2022","author":"Chen","year":"2022","journal-title":"Dis. Markers"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1093\/nar\/gkv1507","article-title":"TCGAbiolinks: an R\/Bioconductor package for integrative analysis of TCGA data","volume":"44","author":"Colaprico","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/nature15393","article-title":"A global reference for human genetic variation","volume":"526","author":"Consortium","year":"2015","journal-title":"Nature"},{"key":"B12","doi-asserted-by":"publisher","first-page":"103556","DOI":"10.1016\/j.dci.2019.103556","article-title":"Defensins: transcriptional regulation and function beyond antimicrobial activity","volume":"104","author":"Contreras","year":"2020","journal-title":"Dev. Comp. Immunol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1038\/s41467-023-38841-7","article-title":"In vivo CRISPR screens reveal Serpinb9 and Adam2 as regulators of immune therapy response in lung cancer","volume":"14","author":"Dervovic","year":"2023","journal-title":"Nat. Commun."},{"key":"B14","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/s41597-022-01697-5","article-title":"Colonomics - integrative omics data of one hundred paired normal-tumoral samples from colon cancer patients","volume":"9","author":"D\u00edez-Villanueva","year":"2022","journal-title":"Sci. data"},{"key":"B15","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1200\/JCO.2017.74.9846","article-title":"Safety and antitumor activity of the anti-programmed death-1 antibody pembrolizumab in patients with advanced esophageal carcinoma","volume":"36","author":"Doi","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1002\/ijc.32002","article-title":"Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in-silico and reallife analysis of three larger gene panels","volume":"144","author":"Endris","year":"2018","journal-title":"Int. J. Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.18.00400","article-title":"Cancer-specific thresholds adjust for whole exome sequencing-based tumor mutational burden distribution","volume":"3","author":"Fernandez","year":"2019","journal-title":"JCO Precis. Oncol."},{"volume-title":"FDA announces approval, CMS proposes coverage of first breakthrough-designated test to detect extensive number of cancer biomarkers","year":"","key":"B19"},{"volume-title":"FDA unveils a streamlined path for the authorization of tumor profiling tests alongside its latest product action","year":"","key":"B20"},{"key":"B21","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.gene.2018.02.007","article-title":"Integrated analysis of gene expression signatures associated with colon cancer from three datasets","volume":"654","author":"Gao","year":"2018","journal-title":"Gene"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1756284820917527","DOI":"10.1177\/1756284820917527","article-title":"Advances in immunotherapy for colorectal cancer: a review","volume":"13","author":"Golshani","year":"2020","journal-title":"Ther. Adv. Gastroenterol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Harview","year":"2014","journal-title":"Nature"},{"key":"B24","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","article-title":"Top 10 challenges in cancer immunotherapy","volume":"52","author":"Hegde","year":"2020","journal-title":"Immunity"},{"volume-title":"illumina","year":"2021","key":"B25"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e127901","DOI":"10.1172\/jci.insight.127901","article-title":"Titin mutation associated with responsiveness to checkpoint blockades in solid tumors","volume":"4","author":"Jia","year":"2019","journal-title":"JCI Insight"},{"key":"B27","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1158\/2326-6066.CIR-16-0143","article-title":"Targeted next generation sequencing identifies markers of response to PD-1 blockade","volume":"4","author":"Johnson","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"573141","DOI":"10.3389\/fonc.2020.573141","article-title":"Significance of tumor mutation burden in immune infiltration and prognosis in cutaneous melanoma","volume":"10","author":"Kang","year":"","journal-title":"Front. Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"573141","DOI":"10.3389\/fonc.2020.573141","article-title":"Significance of tumor mutation burden in immune infiltration and prognosis in cutaneous melanoma","volume":"10","author":"Kang","year":"","journal-title":"Front. Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1634\/theoncologist.2019-0244","article-title":"Tumor mutational burden as a predictive biomarker for response to immune checkpoint inhibitors: a review of current evidence","volume":"25","author":"Klempner","year":"2020","journal-title":"Oncologist"},{"key":"B31","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1101\/gr.129684.111","article-title":"VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing","volume":"22","author":"Koboldt","year":"2012","journal-title":"Genome Res."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.24956.2","article-title":"gprofiler2\u2013 an r package for gene list functional enrichment analysis and namespace conversion toolset g:profiler","volume":"9","author":"Kolberg","year":"2020","journal-title":"F1000Research"},{"key":"B33","doi-asserted-by":"publisher","first-page":"100257","DOI":"10.1016\/j.esmoop.2021.100257","article-title":"Refining patient selection for breast cancer immunotherapy: beyond pd-l1","volume":"6","author":"Kossai","year":"2021","journal-title":"ESMO Open"},{"key":"B34","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nmeth.1923","article-title":"Fast gapped-read alignment with Bowtie 2","volume":"9","author":"Langmead","year":"2012","journal-title":"Nat. Methods"},{"key":"B35","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nature12213","article-title":"Mutational heterogeneity in cancer and the search for new cancer-associated genes","volume":"499","author":"Lawrence","year":"2013","journal-title":"Nature"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","article-title":"The sequence alignment\/map format and SAMtools","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1101\/gr.107524.110","article-title":"The genome analysis toolkit: a mapreduce framework for analyzing next-generation dna sequencing data","volume":"20","author":"McKenna","year":"2010","journal-title":"Genome Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"661","DOI":"10.21037\/tlcr.2018.08.02","article-title":"Methods of measurement for tumor mutational burden in tumor tissue","volume":"7","author":"Mel\u00e9ndez","year":"2018","journal-title":"Transl. Lung Cancer Res."},{"key":"B39","doi-asserted-by":"publisher","first-page":"e1006701","DOI":"10.1371\/journal.pcbi.1006701","article-title":"New functionalities in the tcgabiolinks package for the study and integration of cancer data from gdc and gtex","volume":"15","author":"Mounir","year":"2019","journal-title":"PLOS Comput. Biol."},{"volume-title":"dbgap\/database of genotypes and phenotypes\/national center for biotechnology information, national library of medicine (ncbi\/nlm)","year":"2021","key":"B40"},{"volume-title":"Nhlbi go exome sequencing project (esp)","year":"2021","key":"B41"},{"volume-title":"Picard toolkit","year":"2018","key":"B42"},{"key":"B43","doi-asserted-by":"publisher","first-page":"D130","DOI":"10.1093\/nar\/gkr1079","article-title":"NCBI Reference Sequences (RefSeq): current status, new features and genome annotation policy","volume":"40","author":"Pruitt","year":"2012","journal-title":"Nucleic Acids Res."},{"volume-title":"Q2solution","year":"2021","key":"B44"},{"volume-title":"Qiagen","year":"2021","key":"B45"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1038\/ng.3677","article-title":"Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy","volume":"48","author":"Riaz","year":"2016","journal-title":"Nat. Genet."},{"key":"B47","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1186\/1471-2105-12-480","article-title":"GC-content normalization for RNA-seq data","volume":"12","author":"Risso","year":"2011","journal-title":"BMC Bioinforma."},{"key":"B48","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"Limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"B49","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. mutational landscape determines sensitivity to pd-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"B50","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/nature11282","article-title":"Recurrent r-spondin fusions in colon cancer","volume":"488","author":"Seshagiri","year":"2012","journal-title":"Nature"},{"key":"B51","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1093\/nar\/29.1.308","article-title":"dbSNP: the NCBI database of genetic variation","volume":"29","author":"Sherry","year":"2001","journal-title":"Nucleic Acids Res."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1089\/cmb.2019.0055","article-title":"Tumor mutation burden computation in two pan-cancer precision medicine next-generation sequencing panels","volume":"27","author":"Shu","year":"2020","journal-title":"J. Comput. Biol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.12688\/f1000research.8923.2","article-title":"TCGA Workflow: analyze cancer genomics and epigenomics data using Bioconductor packages","volume":"5","author":"Silva","year":"2016","journal-title":"F1000Research"},{"key":"B54","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to ctla-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.critrevonc.2018.07.001","article-title":"Immuno-oncology in gi tumours: clinical evidence and emerging trials of pd-1\/pd-l1 antagonists","volume":"130","author":"Stein","year":"2018","journal-title":"Crit. Rev. Oncology\/Hematology"},{"key":"B56","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/gcc.22733","article-title":"Tumor mutational burden standardization initiatives: recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions","volume":"58","author":"Stenzinger","year":"2019","journal-title":"Genes. Chromosom. Cancer"},{"key":"B57","doi-asserted-by":"publisher","first-page":"D941-D947","DOI":"10.1093\/nar\/gky1015","article-title":"COSMIC: the catalogue of somatic mutations in cancer","volume":"47","author":"Tate","year":"2018","journal-title":"Nucleic Acids Res."},{"volume-title":"Thermofisher","year":"2021","key":"B58"},{"key":"B59","doi-asserted-by":"publisher","first-page":"453","DOI":"10.21037\/atm.2020.04.02","article-title":"Identification of a six-gene signature associated with tumor mutation burden for predicting prognosis in patients with invasive breast carcinoma","volume":"8","author":"Wang","year":"2020","journal-title":"Ann. Transl. Med."},{"key":"B60","doi-asserted-by":"publisher","first-page":"e164","DOI":"10.1093\/nar\/gkq603","article-title":"ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data","volume":"38","author":"Wang","year":"2010","journal-title":"Nucleic Acids Res."},{"key":"B61","doi-asserted-by":"publisher","first-page":"640","DOI":"10.21037\/atm.2019.10.116","article-title":"Tumor mutational and indel burden: a systematic pan-cancer evaluation as prognostic biomarkers","volume":"7","author":"Wu","year":"","journal-title":"Ann. Transl. Med."},{"key":"B62","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s40425-019-0681-2","article-title":"Designing gene panels for tumor mutational burden estimation: the need to shift from \u2019correlation\u2019 to \u2019accuracy","volume":"7","author":"Wu","year":"","journal-title":"J. Immunother. Cancer"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1038\/nprot.2015.105","article-title":"Genomic variant annotation and prioritization with annovar and wannovar","volume":"10","author":"Yang","year":"2015","journal-title":"Nat. Protoc."},{"key":"B64","doi-asserted-by":"publisher","first-page":"4983","DOI":"10.1038\/s41598-020-61575-1","article-title":"ecTMB: a robust method to estimate and classify tumor mutational burden","volume":"10","author":"Yao","year":"2020","journal-title":"Sci. Rep."},{"key":"B65","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41392-021-00554-y","article-title":"Cytosolic DNA sensing by cGAS: regulation, function, and human diseases","volume":"6","author":"Yu","year":"2021","journal-title":"Sig Transduct. Target Ther."},{"key":"B66","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat. Med."},{"key":"B67","doi-asserted-by":"publisher","first-page":"3849","DOI":"10.1002\/jcp.29279","article-title":"Multi-omics analysis of tumor mutation burden combined with immune infiltrates in bladder urothelial carcinoma","volume":"235","author":"Zhang","year":"2020","journal-title":"J. Cell. Physiol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/s41587-019-0055-9","article-title":"The international cancer genome consortium data portal","volume":"37","author":"Zhang","year":"2019","journal-title":"Nat. Biotechnol."}],"container-title":["Frontiers in Genetics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2024.1285305\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T04:19:37Z","timestamp":1712290777000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2024.1285305\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,5]]},"references-count":68,"alternative-id":["10.3389\/fgene.2024.1285305"],"URL":"https:\/\/doi.org\/10.3389\/fgene.2024.1285305","relation":{},"ISSN":["1664-8021"],"issn-type":[{"type":"electronic","value":"1664-8021"}],"subject":[],"published":{"date-parts":[[2024,4,5]]},"article-number":"1285305"}}